<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839811</url>
  </required_header>
  <id_info>
    <org_study_id>9617</org_study_id>
    <nct_id>NCT02839811</nct_id>
  </id_info>
  <brief_title>Medical Device for Drug Allergy Diagnosis</brief_title>
  <acronym>COBIOPHAD</acronym>
  <official_title>Compact Biophotonic Platform for Drug Allergy Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COBIOPHAD project targets the development of a highly sensitive, selective, and
      multiplexed diagnostic device to provide a quick and inexpensive in vitro test to address the
      most prevalent drug hypersensitivity to betalactams antibiotics, (BLCs). During a
      retrospective study, BLC structures involved in drug hypersensitivity will be identified from
      sera of allergic patients (versus controls) and coupled on the device.

      A prospective study will be performed for the recruitment of samples corresponding to
      patients with known IgE hypersensitivity to BLCs based on results from allergy tests and
      clinical history. Controls will include: non-allergic individuals with known tolerance to
      betalactams. The samples will be used for the validation of the COBIOPHAD device in real
      settings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the COBIOPHAD device in diagnosing immediate hypersensitivity to BLC</measure>
    <time_frame>up to 1 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of the COBIOPHAD device in diagnosing immediate hypersensitivity to BLC</measure>
    <time_frame>up to 1 hour</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Drug Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>immediate hypersensitivity to BLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immediate hypersensitivity to BLC by In vitro diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immediate hypersensitivity to BLC</intervention_name>
    <description>immediate hypersensitivity to BLC by In vitro diagnosis</description>
    <arm_group_label>immediate hypersensitivity to BLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - patients with known hypersensitivity to BLC (proven by means of in vivo tests) (cases)

        Exclusion Criteria:

          -  patients with contraindications to BLC allergy work-up

          -  patient refusal to enter the study

          -  vulnerable patients according to French regulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anca CHIRIAC, MD</last_name>
    <email>a-chiriac@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca CHRIAC, MD</last_name>
      <email>a-chiriac@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>anca chiriac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Betalactams</keyword>
  <keyword>In vitro diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Drug Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

